CBRE Arranges Expansion Lease for Cour Pharmaceuticals
CBRE has secured a 14,000 sq. ft. lease expansion for Cour Pharmaceuticals at the Illinois Science and Technology Park in Skokie, IL, bringing their total leased space to approximately 25,000 sq. ft. This move responds to the rising demand for medical research space in the Chicago area. The Illinois Science + Technology Park offers significant facilities, and Chicago has seen a 30% increase in venture capital funding for life sciences, totaling $491.8 million in Q1 2021. The city is also experiencing substantial growth in lab space, with nearly 1 million sq. ft. delivered or under construction.
- Expansion of lease by 14,000 sq. ft. signifies growth in demand for life sciences space.
- Total leased space for Cour Pharmaceuticals now reaches around 25,000 sq. ft., enhancing operational capabilities.
- Chicago experienced a 30% increase in life sciences venture capital funding, totaling $491.8 million in Q1 2021.
- Significant growth in lab space with nearly 1 million sq. ft. delivered or under construction, addressing previous space shortages.
- None.
CHICAGO, Nov. 18, 2021 /PRNewswire/ -- To meet the increasing demand for medical research space in the Chicagoland area, CBRE is expanding a 14,000 sq. ft lease to expand Cour Pharmaceuticals' life science and emergency biotechnology footprint within the Illinois Science and Technology Park in Skokie, Ill. With the addition, Cour Pharmaceuticals now leases around 25,000 sq. ft. in the park.
The Illinois Science + Technology Park started with the former corporate headquarters of pharmaceutical giant G.D. Searle and has since created a community of scientists, inventors, and innovators. Upon completion of its redevelopment the Illinois Science + Technology Park will offer up to 2 million square feet of office and state-of-the-art facilities including chemistry and biology labs, CGMP facilities, as well as state-of-the-art clinical research labs.
"This is an exciting expansion that is illustrative of the momentum we are seeing in this sector," said Saad. "Chicago presents a plethora of desirable fundamentals that are tailor made for growth-stage life science companies."
"Continued rapid growth for high-potential life science startups are emerging in Chicago and in addition to talent, life sciences companies like COUR will continue to need access to more specialized wet and dry lab space along with capital," said COUR Pharmaceuticals CEO John Puisis. "Ideal for both emerging and established life sciences operations, CBRE can help your biotech business take the next step in its path toward success with its a growing portfolio of best-in-class life science developments."
According to a recent CBRE report, Chicago continues to attract significant venture capital funding, posting a Q1 annual amount of
Among the top 12 U.S. life-science markets, Chicago has seen a substantial uptick in inventory, with nearly 1 million sq. ft. of Class A lab space delivered or under construction since 2020, primarily in Fulton Market. Historically, a lack of available lab space had been a significant impediment to the growth of Chicago's research-based life sciences sector. Chicago has 704,545 sq. ft. of space currently under construction, all of which being new, ground-up construction that is expected to deliver by the end of 2024.
CBRE's David Saad represented the Cour Pharma in the expansion transaction.
About CBRE Group, Inc.
CBRE Group, Inc. (NYSE: CBRE), a Fortune 500 and S&P 500 company headquartered in Dallas, is the world's largest commercial real estate services and investment firm (based on 2020 revenue). The company has more than 100,000 employees serving clients in more than 100 countries. CBRE serves a diverse range of clients with an integrated suite of services, including facilities, transaction and project management; property management; investment management; appraisal and valuation; property leasing; strategic consulting; property sales; mortgage services and development services. Please visit our website at www.cbre.com.
About COUR
COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. COUR's platform of immune-modifying nanoparticles treats the root cause of immune disease, unlike traditional approaches, which only minimize symptoms using toxic immune suppression. COUR's lead product for celiac disease, partnered with Takeda Pharmaceutical Company, is the first demonstration of induction of antigen-specific immune tolerance in any autoimmune disease. Data from clinical and preclinical settings demonstrate the opportunity for the COUR nanoparticle platform to address a wide range of immune and inflammatory conditions. The underlying technology was acquired from Northwestern University and draws from more than 30 years of research by the laboratory of Stephen D. Miller, Ph.D., the Judy E. Guggenheim Research Professor of Microbiology-Immunology.
Contact:
CBRE:
Casey Davison
+1 314 655 5825
casey.davison@cbre.com
COUR Pharmaceuticals:
Julie Ferguson
+1 312 385 0098
Julie@jfprmedia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cbre-arranges-expansion-lease-for-cour-pharmaceuticals-301428248.html
SOURCE COUR Pharmaceuticals
FAQ
What recent expansion did CBRE arrange for Cour Pharmaceuticals?
How much total space does Cour Pharmaceuticals now lease?
What is the significance of the Illinois Science and Technology Park for life sciences?
What was the total venture capital funding for Chicago's life sciences sector in Q1 2021?
What trends are driving growth in Chicago's life sciences market?
